TY - JOUR
T1 - The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers
AU - Turner, Bruce C.
AU - Ottey, Michelle
AU - Zimonjic, Drazen B.
AU - Potoczek, Magdalena
AU - Hauck, Walter W.
AU - Pequignot, Edward
AU - Keck-Waggoner, Catherine L.
AU - Sevignani, Cinzia
AU - Aldaz, C. Marcelo
AU - McCue, Peter A.
AU - Palazzo, Juan
AU - Huebner, Kay
AU - Popescu, Nicholas C.
PY - 2002/7/15
Y1 - 2002/7/15
N2 - In various studies of sporadic breast cancers, 40-70% were strongly positive for fragile histidine triad (Fhit) protein expression, whereas only 18% of BRCA2 mutant breast cancers demonstrated strong Fhit expression, suggesting that the BRCA2 repair function may be necessary to retain intact fragile common chromosome fragile site 3B (FRA3B)/FHIT loci. In the current study, 22 breast tumors with deleterious BRCA1 mutations were analyzed for Fhit expression by immunohistochemistry in a case-control matched pair analysis. Loss of Fhit expression was significantly more frequent in the BRCA1 cancers compared with sporadic breast tumors (9% Fhit positive versus 68% Fhit positive), suggesting that the BRCA1 pathway is also important in protecting the FRA3B/FHIT locus from damage. To investigate the relationship between repair gene deficiencies and induction of chromosome fragile sites in vitro, we have analyzed the frequency of aphidicolin induction of chromosome gaps and breaks in PMS2-, BRCA1-, MSH2-, MLH1-, FHIT-, and TP53-deficient cell lines. Each of the repair-deficient cell lines showed elevated expression of chromosome gaps and breaks, consistent with the proposal that proteins involved in mismatch and double-strand break repair are important in maintaining the integrity of common fragile regions. Correspondingly, genes at common fragile sites may sustain elevated levels of DNA damage in cells with deficient DNA repair proteins such as those mutated in several familial cancer syndromes.
AB - In various studies of sporadic breast cancers, 40-70% were strongly positive for fragile histidine triad (Fhit) protein expression, whereas only 18% of BRCA2 mutant breast cancers demonstrated strong Fhit expression, suggesting that the BRCA2 repair function may be necessary to retain intact fragile common chromosome fragile site 3B (FRA3B)/FHIT loci. In the current study, 22 breast tumors with deleterious BRCA1 mutations were analyzed for Fhit expression by immunohistochemistry in a case-control matched pair analysis. Loss of Fhit expression was significantly more frequent in the BRCA1 cancers compared with sporadic breast tumors (9% Fhit positive versus 68% Fhit positive), suggesting that the BRCA1 pathway is also important in protecting the FRA3B/FHIT locus from damage. To investigate the relationship between repair gene deficiencies and induction of chromosome fragile sites in vitro, we have analyzed the frequency of aphidicolin induction of chromosome gaps and breaks in PMS2-, BRCA1-, MSH2-, MLH1-, FHIT-, and TP53-deficient cell lines. Each of the repair-deficient cell lines showed elevated expression of chromosome gaps and breaks, consistent with the proposal that proteins involved in mismatch and double-strand break repair are important in maintaining the integrity of common fragile regions. Correspondingly, genes at common fragile sites may sustain elevated levels of DNA damage in cells with deficient DNA repair proteins such as those mutated in several familial cancer syndromes.
KW - Acid Anhydride Hydrolases
KW - Animals
KW - Aphidicolin/pharmacology
KW - BRCA1 Protein/deficiency
KW - Breast Neoplasms/genetics
KW - Chromosome Aberrations
KW - Chromosome Breakage
KW - DNA Repair/genetics
KW - Gene Silencing
KW - Genes, BRCA1
KW - Humans
KW - Mice
KW - Neoplasm Proteins/biosynthesis
KW - Tumor Cells, Cultured
UR - http://www.scopus.com/inward/record.url?scp=0037099669&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000176871500027&DestLinkType=FullRecord&DestApp=WOS
M3 - Article
C2 - 12124341
SN - 0008-5472
VL - 62
SP - 4054
EP - 4060
JO - Cancer Research
JF - Cancer Research
IS - 14
ER -